On August 16, 2019 Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, reported that the Company will report first half 2019 financial results and business highlights on the evening of Thursday, August 22, 2019 (Press release, Celyad, AUG 16, 2019, View Source [SID1234538816]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Following the press release, Celyad management will host a conference call on Friday, August 23 at 2pm CEDT / 8am EDT to discuss first half 2019 results and provide an update on the Company’s recent progress and upcoming milestones.
Participants may access the conference call by dialing any of the following numbers:
Belgium, Brussels +32 (0) 24 01 70 35
France, Paris +33 (0)1 76 72 89 28
United States: +1 917 720 0181
International: +44 (0) 2071 928501
Conference ID: 3547725